Jennison Associates LLC Sells 27,163 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Jennison Associates LLC decreased its position in IQVIA Holdings Inc. (NYSE:IQV) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,336 shares of the medical research company’s stock after selling 27,163 shares during the quarter. Jennison Associates LLC’s holdings in IQVIA were worth $30,389,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of IQV. Laurel Wealth Advisors LLC increased its position in IQVIA by 1.1% during the third quarter. Laurel Wealth Advisors LLC now owns 4,710 shares of the medical research company’s stock worth $927,000 after acquiring an additional 50 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of IQVIA by 18.1% in the third quarter. Parkside Financial Bank & Trust now owns 346 shares of the medical research company’s stock valued at $68,000 after buying an additional 53 shares during the period. Private Advisor Group LLC lifted its stake in shares of IQVIA by 1.2% in the third quarter. Private Advisor Group LLC now owns 4,818 shares of the medical research company’s stock valued at $948,000 after buying an additional 56 shares during the period. B. Riley Wealth Advisors Inc. lifted its stake in shares of IQVIA by 1.6% in the third quarter. B. Riley Wealth Advisors Inc. now owns 3,568 shares of the medical research company’s stock valued at $702,000 after buying an additional 56 shares during the period. Finally, Greenleaf Trust lifted its stake in shares of IQVIA by 1.9% in the fourth quarter. Greenleaf Trust now owns 3,154 shares of the medical research company’s stock valued at $730,000 after buying an additional 58 shares during the period. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of several research reports. BTIG Research initiated coverage on shares of IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 target price for the company. Truist Financial raised their price target on shares of IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Evercore ISI raised their price target on shares of IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Barclays raised their price target on shares of IQVIA from $260.00 to $265.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Finally, Guggenheim lowered shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $256.80.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,000 shares of IQVIA stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the sale, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 over the last ninety days. Company insiders own 1.60% of the company’s stock.

IQVIA Trading Up 0.9 %

Shares of NYSE IQV opened at $240.84 on Thursday. The company’s fifty day moving average is $245.50 and its 200-day moving average is $222.69. The stock has a market cap of $43.71 billion, a price-to-earnings ratio of 33.04, a P/E/G ratio of 2.31 and a beta of 1.50. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a quick ratio of 0.86, a current ratio of 0.86 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. During the same period last year, the business posted $2.54 earnings per share. The firm’s quarterly revenue was up 3.5% on a year-over-year basis. Equities research analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.